Don Soland

Don Soland

No open positions remaining

Net worth: 953 928 $ as of 31/05/2026

67 year
Health Technology
Consumer Services

Profile

Daniel B. Soland was Director-Worldwide Marketing Operations & VP at Corixa Corp.
from 1993 to 2002.
Served as President & Chief Executive Officer at Epigenesis Pharmaceuticals LLC from 2002 to 2005.
Held the position of President at Seqirus Vaccines Ltd. from 2005 to 2006.
Was President-Chiron Vaccines at Chiron Corp.
from 2005 to 2006.
Chief Operating Officer & Senior Vice President at Viropharma, Inc. from 2008 to 2014.
Chief Operating Officer & Senior Vice President at Shire ViroPharma, Inc. from 2008 to 2014.
Chief Executive Officer & Executive Director at uniQure NV in 2016.
Independent Director at ACADIA Pharmaceuticals, Inc. from 2015 to 2025.
Independent Director at DBV Technologies SA from 2015 to 2025.
Non-Executive Director at Oxford Biomedica Plc from 2015 to 2016.
Independent Director at KalVista Pharmaceuticals, Inc. from 2019 to 2022.
Chief Operating Officer & Senior Vice President at Idera Pharmaceuticals, Inc. from 2020 to 2022.
Director at Tarsa Therapeutics, Inc. Education includes undergraduate studies at the University of Iowa.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
29/05/2025 44,041 ( 0.03% ) 953 928 $ 31/05/2026

Former positions of Don Soland

CompaniesPositionEnd
ACADIA PHARMACEUTICALS INC. Director/Board Member 30/10/2025
DBV TECHNOLOGIES Director/Board Member 18/09/2025
Chief Operating Officer 28/09/2022
KALVISTA PHARMACEUTICALS, INC. Director/Board Member 26/05/2022
UNIQURE N.V. Chief Executive Officer 22/09/2016
See the detail of Don Soland's experience

Training of Don Soland

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

60

1st degree connections

14

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies14

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Viropharma, Inc.

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!